Magnesium-containing oxytocin formulations and methods of use
US12156897B2 · kind B2 · utility
0Cited by
58References
29Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 12, 2017 |
| Grant date | Dec 3, 2024 |
| Priority date | — |
| Expiry date | Sep 7, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/22
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are methods and compositions for the treatment of autism spectrum disorder, related disorders and symptoms of such disorders, comprising co-administration of an oxytocin peptide and magnesium ions. Co-administration of an oxytocin peptide and magnesium ions results in a synergistic or enhanced effect on reducing social and communication deficits in a patient suffering from an autism spectrum disorder.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.